Incyte Corporation

Incyte Corporation Earnings Recaps

INCY Health Care 3 recaps
Q1 2026 Apr 30, 2026

Shares climbed 3.5% post-earnings as solid 20% net sales growth, broad portfolio momentum, and pipeline advancement outpaced investor expectations. Management also unveiled multiple upcoming product launches and a refreshed executive team, supporting confidence in the company’s growth transition beyond Jakafi.

Key takeaways
  • First quarter revenue reached $1.27 billion, up 21% year-over-year, with net sales of $1.1 billion (+20%).
  • Double-digit growth across all marketed products: Jakafi sales rose 7%, while the core business excluding Jakafi jumped 63% year-over-year.
  • The company expects four new product launches within 12 months, including Jakafi XR (anticipated mid-year), Opzelura (European AD), Monjuvi (first-line DLBCL), and povorcitinib (HS).
  • Positive late-stage pipeline momentum: FDA accepted povorcitinib application for HS ahead of schedule; Phase III studies underway in hematology, oncology, and immunology.
  • Recent executive appointments—including a new CFO and expanded commercial leadership—aim to strengthen operational execution and launch readiness for 2026 and beyond.
Full recap
Q3 2025 Oct 28, 2025

Incyte reported a strong Q3 2025, with total revenues of $1.37 billion and product sales of $1.15 billion, reflecting year-over-year growth of 20% and 19%, respectively, driven by robust demand for Jakafi and Opzelura.

Key takeaways
  • Jakafi sales reached $791 million, a 7% increase, with broad-based growth across all indications and market share leadership maintained in MF.
  • Opzelura achieved $188 million in sales, up 35% year-over-year, bolstered by strong prescription demand and improved formulary access.
  • Niktimvo exceeded launch expectations with $46 million in Q3 sales, capturing 13% of the third-line GVHD opportunity shortly after launch.
  • Incyte raised its full-year guidance for Jakafi to $3.05 billion to $3.075 billion based on current momentum.
  • Upcoming product launches in 2026 are positioned to enhance growth prospects, including ruxolitinib XR and additional indications for Opzelura.
Full recap
Q2 2025 Aug 2, 2025

Incyte's Q2 2025 results reflect strong product performance and promising pipeline advancements, positioning the company for sustained growth despite leadership transition and strategic realignment.

Key takeaways
  • Opzelura and Niktimvo are demonstrating solid sales momentum, with Opzelura expanding its prescriber base significantly and showing potential for new indications.
  • The company is actively focusing on accelerating product development, particularly for the promising asset 989, which targets specific mutations in hematological malignancies.
  • Incyte's robust R&D capabilities coupled with a strategic emphasis on capital allocation aim to enhance shareholder value and foster new product growth through both internal development and judicious business development opportunities.
Full recap